GLP-1 drugs linked to a small but real rise in optic nerve stroke risk
A meta-analysis of over 1.5 million patients finds GLP-1 drugs raise NAION odds by 70%, but absolute risk stays tiny, about one extra case per 2,700 users.
Summary
Researchers pooled 15 studies covering more than 1.5 million people to test whether GLP-1 receptor agonists, the drug class behind many diabetes and weight-loss medications, are linked to nonarteritic ischemic optic neuropathy (NAION). NAION is a sudden form of vision loss caused by reduced blood flow to the optic nerve. GLP-1 use was associated with 70% higher odds of NAION (OR 1.70; 95% CI 1.23-2.36). The absolute risk was small: about 0.09% in users, a 0.037% risk difference, or roughly one extra case per 2,700 people treated. There was no increase in overall eye events. The authors stress that this modest signal should be weighed against the drugs' established benefits for survival and heart, kidney, and metabolic health. They also call for long-term post-marketing safety studies.
Detailed Summary
GLP-1 receptor agonists are now widely used for type 2 diabetes, obesity, and cardiovascular risk reduction. Case reports and observational studies have raised concern that they may be linked to NAION, a sudden, usually painless vision loss with no proven treatment. Clarifying this risk matters for patients and clinicians weighing these drugs.
The authors searched PubMed, Embase, and the Cochrane Library in August 2025. They pooled 15 longitudinal studies, including 8 trials, with more than 1.5 million patients. Using random-effects Peto and inverse-variance models, they estimated odds ratios and absolute risks for NAION. Any ocular event was a secondary outcome.
GLP-1 RA use was associated with higher NAION odds (OR 1.70; 95% CI 1.23-2.36). The estimate was consistent across randomized studies (OR 2.36; 0.85-6.53) and nonrandomized studies (OR 1.64; 1.15-2.35), with no significant heterogeneity (P = 0.51). Absolute NAION risk in the GLP-1 RA group was 0.09%, a risk difference of 0.037%, or a number needed to harm of about 2,700. Overall ocular events did not differ (OR 0.95; 0.86-1.05).
The findings point to a modest but statistically consistent signal for a rare, serious event. The authors argue the result supports long-term post-marketing surveillance. They also say it should be read alongside the well-established mortality and cardio-kidney-metabolic benefits of these drugs. For most patients the absolute risk is very small, though clinicians may want to be attentive in people with known optic nerve risk factors.
Caveats apply. This summary draws on the abstract alone. The randomized-trial estimate had a wide confidence interval that included no effect. Most of the evidence is observational, so confounding by diabetes, obesity, and related vascular conditions cannot be excluded. Drug-specific and dose-specific effects were not described in the abstract.
Key Findings
- GLP-1 RA use was associated with 70% higher odds of NAION (OR 1.70; 95% CI 1.23-2.36) across 15 studies.
- Absolute NAION risk with GLP-1 RAs was 0.09%, a 0.037% risk difference, or number needed to harm of about 2,700.
- Randomized studies pointed the same way (OR 2.36) but with a wide interval crossing 1 (0.85-6.53).
- Nonrandomized studies showed OR 1.64 (1.15-2.35), with no significant heterogeneity between study types (P = 0.51).
- Overall ocular adverse events did not differ with GLP-1 RA use (OR 0.95; 95% CI 0.86-1.05).
Methodology
Systematic review and meta-analysis searching PubMed, Embase, and Cochrane Library in August 2025. Fifteen longitudinal studies (8 trials; over 1.5 million patients) were pooled using random-effects Peto and inverse-variance models for odds ratios and absolute risk. The primary outcome was NAION; any ocular event was secondary.
Study Limitations
Only the abstract was available, so study-level details such as individual agents, doses, populations, and follow-up were not assessed. The randomized estimate was statistically non-significant with a wide confidence interval, and most data came from nonrandomized studies vulnerable to confounding by diabetes, obesity, and vascular risk. NAION is rare, so event counts and detection methods may limit precision, and causality cannot be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: